-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – REGN-5459 in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - REGN-5459 in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. REGN-5459 in Relapsed Multiple Myeloma Drug Details: REGN-5459 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gene Therapy to Target KK-LC-1 for Oncology in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy to Target KK-LC-1 for Oncology in Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Gene Therapy To Target Kk-Lc-1 For Oncology...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GB-2064 in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GB-2064 in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.GB-2064 in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) Drug Details:GB-2064 (PAT-1251)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IO-108 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IO-108 in Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IO-108 in Colorectal Cancer Drug Details: IO-108 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Aceclofenac + Eperisone Sr) in Muscle Spasm
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.(Aceclofenac + Eperisone Sr) in Muscle SpasmDrug Details:A fixed-dose combination of aceclofenac and eperisone SR is...
-
Sector Analysis
Green Bites – Key Disruptive Forces in Sustainable Nutrition
Disruptive Forces in Sustainable Nutrition Report Overview Advanced developments such as edible insects, food 3D printing, and plant-based proteins are redefining food efficiency and environmental impact in the sustainable nutrition domain. Innovation Curve: Consumer Buy the Full Report to Know More about the Disruptive Forces in Sustainable Nutrition Download a Free Report Sample The ‘Green Bites – Key Disruptive Forces in Sustainable Nutrition’ FutureTech series report categorizes the key innovation areas in sustainable nutrition as emerging, accelerating, and maturing. The...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Aceclofenac + Eperisone Sr) in Low Back Pain
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.(Aceclofenac + Eperisone Sr) in Low Back Pain Drug Details:A fixed-dose combination of aceclofenac and eperisone...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – NVP-1705
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry NVP-1705 Drug Details NVP-1705 is under development for the treatment of idiopathic (essential) hypertension...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – NVP-1901
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry NVP-1901 Drug Details NVP-1901 is under development for the treatment of diabetes. It is...